Treatment patterns in women with postmenopausal osteoporosis using abaloparatide: a real-world observational study

Deborah T Gold; Tammy Beckett; Chad Deal; Andrew L James; Mahshid Mohseni; Abigail McMillan; Tom Bailey; Leny Pearman; John Caminis; Yamei Wang; Setareh A Williams; Jacqueline M Kernaghan

doi:10.1007/s00198-024-07070-z

Treatment patterns in women with postmenopausal osteoporosis using abaloparatide: a real-world observational study

Osteoporos Int. 2024 Apr 24. doi: 10.1007/s00198-024-07070-z. Online ahead of print.

Authors

Affiliations

¹ Departments of Psychiatry & Behavioral Sciences and Sociology, Duke University Medical Center, Durham, NC, USA.
² Department of Orthopaedics, Orthopaedic Associates of Grand Rapids Research and Education Institute, Grand Rapids, MI, USA.
³ Department of Rheumatology, Center for Osteoporosis and Metabolic Bone Disease, The Cleveland Clinic Foundation, Cleveland, OH, USA.
⁴ Proactive Orthopaedics at Columbia Orthopaedic Group LLP, Adult Health CNS, Columbia, MO, USA.
⁵ Department of Medicine, Division of Bone and Mineral Diseases, Washington University School of Medicine, St Louis, MO, USA.
⁶ Observational Research Adelphi Real World, Bollington, Macclesfield, UK.
⁷ Global Medical Affairs, Radius Health, Inc, Boston, MA, USA.
⁸ Biostatistics, Radius Health, Inc, Boston, MA, USA. yawang@radiuspharm.com.
⁹ Cobbs Creek Healthcare, Newtown Square, PA, USA.
¹⁰ Osteoporosis Center of Delaware County, Prospect Health Access Network, Springfield, PA, USA.

PMID: 38653862
DOI: 10.1007/s00198-024-07070-z

Abstract

Review of medical records from 173 women with osteoporosis who received abaloparatide treatment revealed that 96.0% had at least one visit for osteoporosis management and 55.5% had medication support group access. The most common reasons for discontinuing treatment were financial (31.2%) and tolerability (22.8%). Most patients (64.8%) completed treatment as prescribed.

Purpose: Abaloparatide is approved for the treatment of women with postmenopausal osteoporosis at high risk for fracture. This study evaluated real-world treatment patterns for patients new to abaloparatide, regardless of osteoporosis treatment history.

Methods: Data for patients with ≥ 1 prescription for abaloparatide were collected retrospectively from six academic and clinical practice settings across the US.

Results: A total of 173 patients were enrolled (mean [SD] age, 69.8 [7.4] years). At the time of abaloparatide treatment initiation, 78.6% had received other osteoporosis medications. Mean (SD) time from discontinuation of osteoporosis medications prior to initiation of abaloparatide was 1.7 (3.2) years. Twenty-four months of follow-up data from the initiation date of abaloparatide was collected from 94.0% of patients and 6.0% of patients had 12-24 months of follow-up. During the follow-up period, 96.0% of patients had at least one visit for osteoporosis management and 55.5% had access to a medication support program. The median duration of therapy was 18.6 months and 105/162 (64.8%) completed abaloparatide treatment as prescribed. The most common reasons for treatment discontinuation were financial (31.2%) and tolerability (22.8%). Following completion of a course of treatment with abaloparatide, 82/162 (50.6%) patients transitioned to another osteoporosis medication. The median time between abaloparatide treatment course completion and the initiation of follow-on medication was 21 days.

Conclusion: Most patients completed treatment with abaloparatide as prescribed, and over half continued with an antiresorptive agent. This favorable conduct may be the result of regular follow-up visits and accessibility to both medication and patient support services.

Keywords: Abaloparatide; Anabolic therapy; Osteoporosis; Treatment patterns; Treatment persistence.